{"type":"trials","record":{"id":41612,"source_id":"clinicaltrials-gov","external_id":"NCT07418177","title":"Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD","brief_summary":"Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial (HiPSC-RPE) Cells Subretinal Transplantation in Late-Stage Age-Related Macular Degeneration(AMD) Patients","overall_status":"Not Yet Recruiting","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"The First Affiliated Hospital with Nanjing Medical University","enrollment":9,"countries":["China"],"start_date":"2026-02-10","completion_date":"2028-12-31","last_update_date":"2026-02-18","source_url":"https://clinicaltrials.gov/study/NCT07418177","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 80 Years","comparator":null,"organization":"The First Affiliated Hospital with Nanjing Medical University","interventions":["HiPSC-RPE cells","Erlotinib (150 mg daily)","Prednisone"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of subjects with adverse events — Two years following transplantation","Assessment of visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. — From en…","Assessment of visual function changes-microperimetry — From enrollment to the end of visiting at 2 years"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["AMD - Age-Related Macular Degeneration","HiPSC-RPE cells","Erlotinib (150 mg daily)","Prednisone"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07418177","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-02-10 to 2028-12-31","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.841Z","intervention":["HiPSC-RPE cells","Erlotinib (150 mg daily)","Prednisone"],"participants":9,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of subjects with adverse events — Two years following transplantation","Assessment of visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. — From en…","Assessment of visual function changes-microperimetry — From enrollment to the end of visiting at 2 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41612","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}